- Trial phase
- Phase 2/3 (pivotal)
- Time to market
- If the OS readout is positive, a regulatory filing could follow in 2027-2028. If OS also misses, the program is likely terminated for this indication.
- Why 4/10
- The next hard catalyst is the overall survival (OS) readout from the AHEAD-MERIT Phase 2/3 trial, but no specific date has been announced. The PFS endpoint was already missed on October 13, 2026, so the binary event has passed. BNT113 is one of several late-stage oncology assets at a company with a EUR 16.2 billion cash position, so it is not a make-or-break drug.
The next catalyst is the overall survival (OS) readout from the AHEAD-MERIT trial, which has no announced date. If OS is positive, it could salvage the program despite the PFS miss; if OS also misses, BNT113 is effectively dead for this indication. Watch for BioNTech's disclosures on the timing of the OS analysis.
Price Chart
Executive Summary
Tenumomeran/raplemomeran (BNT113) is BioNTech's mRNA-based therapeutic cancer vaccine targeting HPV16-positive head and neck squamous cell carcinoma (HNSCC). On October 13, 2026, the Phase 2/3 AHEAD-MERIT trial failed its first dual primary endpoint of progression-free survival (PFS) for BNT113 plus pembrolizumab versus pembrolizumab alone. The Independent Data Monitoring Committee recommended continuing the trial to evaluate the second primary endpoint of overall survival (OS), which remains the next binary catalyst with no announced date. BioNTech has a diversified late-stage oncology pipeline and a EUR 16.2 billion cash position, so BNT113 is not a company-threatening asset, but the PFS miss significantly dented analyst confidence in the program.
How It Works
Tenumomeran/raplemomeran (BNT113) is an mRNA-based therapeutic cancer vaccine. It delivers genetic instructions (mRNA) that teach the patient's own cells to produce two proteins (E6 and E7) found on HPV16-positive cancer cells. This trains the immune system to recognize and attack tumors expressing those proteins. It is given intravenously and is designed to work alongside checkpoint inhibitor drugs like pembrolizumab (Keytruda).
Trial Status
The AHEAD-MERIT trial (NCT04534205) is a Phase 2/3 study of BNT113 plus pembrolizumab vs. pembrolizumab alone in first-line unresectable recurrent or metastatic HPV16-positive HNSCC. The Phase 3 portion's first dual primary endpoint (PFS) was missed on October 13, 2026. The trial continues to follow patients for the second dual primary endpoint of overall survival (OS).
The Two-Sided Case
Upcoming Catalysts
- Overall survival (OS) readout from AHEAD-MERIT Phase 2/3 trial (no date announced)
- Potential regulatory filing if OS is positive
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BioNTech SE 6-K BNTX ·Originating report